Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Expert Opinion
    • St Jude releases cyber...

    St Jude releases cyber updates for heart devices after US probe

    Written by supriya Published On 2017-01-10T11:32:13+05:30  |  Updated On 10 Jan 2017 11:32 AM IST
    St Jude releases cyber updates for heart devices after US probe

    Abbott Laboratories (ABT.N) moved to protect patients with its St. Jude heart implants against possible cyber attacks, releasing a software patch that the firm said will reduce the "extremely low" chance of them being hacked.


    The company disclosed the moves some five months after the U.S. government launched a probe into claims the devices were vulnerable to potentially life-threatening hacks that could cause implanted devices to pace at potentially dangerous rates or cause them to fail by draining their batteries..


    The Food and Drug Administration and the Department of Homeland Security said that St. Jude's software update addresses some, but not all, known cyber security problems in its heart devices.


    The patch that Abbott began pushing out to patients on Monday addresses vulnerabilities that present the greatest risk to patients and prevent hackers from accessing the device, said FDA spokeswoman Angela Stark.


    "The patch is intended to reduce the risk of unauthorized individuals exploiting the vulnerability and support patient safety," she said. "The FDA has maintained this focus on addressing patient safety first and foremost throughout its investigation."


    A Department of Homeland Security spokesman said he had no immediate comment on the remaining problems.


    St. Jude spokeswoman Candace Steele Flippin declined to identify specific problems, but said: "The cybersecurity landscape is evolving. St. Jude Medical has worked with, and continues to work with, the FDA and DHS to update and improve the security of our technology."


    MedSec Chief Executive Justine Bone said in a statement that "a multitude of severe vulnerabilities" were not fixed in the security update.


    They include the ability to issue an unauthorized command to a cardiac implant from a device other than St. Jude's Merlin@Home device, Bone said.


    Monday marked the first time that the FDA and DHS had confirmed that St. Jude devices were vulnerable to hacking. They said they knew of no cyber attacks on patients with the company's cardiac implants.


    The FDA said that the benefits of continuing treatment outweighed cyber risks. DHS said only an attacker "with high skill" could exploit the vulnerability.


    They launched the probe in August after short-selling firm Muddy Waters and cyber security firm MedSec Holdings said the devices were riddled with security flaws that made them vulnerable to potentially life-threatening hacks.


    When Muddy Waters went public with the claims, it also disclosed it was shorting St. Jude Medical, which was preparing to sell itself to Abbott.


    The short-selling firm said it believed that disclosure of the vulnerabilities could cause the $25 billion deal to fall apart, but Abbott last week completed its acquisition of St. Jude, one of the world's biggest makers of implantable cardiac devices.


    Muddy Waters founder Carson Block said he felt the release of the software patch "effectively vindicates" the research produced by his firm and MedSec.


    As St. Jude announced the security patch, it declined comment on a lawsuit it filed against Muddy Waters and MedSec in September. It accused them of perpetrating a "willful and malicious scheme to manipulate the securities markets for their own financial windfall."


    MedSec said St. Jude has not dropped the lawsuit.


    Abbott shares closed down 0.1 percent at $40.74. The S&P 500, by comparison, dipped 0.3 percent.

    AbbottAngela Starkcyber attacksheart devicesSt JudeUS Food and Drug AdministrationUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya
    supriya
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok